Aging-associated differences in mammary tumor–initiating populations and immune evasion pathways in breast cancer
Abstract
Aging is a major risk factor for breast cancer, yet how it shapes tumor development, molecular phenotype, and immune evasion remains incompletely understood. Deciphering how aging influences cancer evolution is critical for improving risk assessment, prevention, and treatment. Here, using a N-nitroso-N-methylurea (NMU)-induced rat mammary tumor model that recapitulates key features of human breast cancer, we integrated bulk and single-cell transcriptomics, whole-exome sequencing, and histopathological analysis to dissect age-associated differences in mammary tumorigenesis. We found that the age at NMU exposure critically influences tumor incidence, mutational burden, molecular subtype, and the tumor immune microenvironment. Tumors arising in aged rats originated from aging luminal progenitor-like cells, exhibited increased genomic instability, reduced immune cell infiltration, and impaired antigen presentation linked to loss of heterozygosity at chromosome (Chr) 20p. The age-associated epithelial and immune changes we identified were conserved in human breast cancers, where the loss of the homologous Chr 6p region correlated with reduced lymphocyte infiltration and shorter relapse-free survival. These findings reveal that aging profoundly affects tumor-initiating cell populations and promotes immune evasion through chromosomal instability-driven defects in antigen presentation. Our work provides a molecular basis for understanding disease onset and progression that may impact efficacy of immunotherapy in older breast cancer patients.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (11)
Pengze Yan
Department of Medical Oncology, Dana-Farber Cancer Institute
Triet Bui
Department of Medical Oncology, Dana-Farber Cancer Institute
Ernesto Rojas Jimenez
Department of Medical Oncology, Dana-Farber Cancer Institute
Yanan Kuang
Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute
Shidong Xu
Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute
Cloud P. Paweletz
Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute
Hodaya Haimov
The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev
Menachem Sklartz
The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev
Ofir Cohen
The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev
Sandra S. McAllister
Kornelia Polyak
Department of Medical Oncology, Dana-Farber Cancer Institute